In a phase I clinical trial, intramuscular injection of Ad2/HIF-1α/VP16 reduced RP and promoted ulcer healing in some patients 89; however, in a phase III clinical trial, an increase in edema rate was observed, probably due to continuously activated HIF-1α 89. Here, HIF1A is linked to ulcer disease.